Target intelligence / Profile preview

Effects on gut microbiome

Molecular classification
Other (not a molecule, receptor, enzyme, transporter, or gene)
01

Overview

“Effects on gut microbiome” is not a specific molecular target but rather refers to any intervention or process that alters the composition and/or function of the community of microorganisms residing in the gastrointestinal tract. The term encompasses diverse strategies such as probiotics, prebiotics, fecal microbiota transplantation, bacteriophage therapy, and dietary modifications aimed at restoring healthy microbial balance. These approaches are being explored for their potential to treat gastrointestinal diseases like IBS and IBD by modulating inflammation and improving barrier integrity; they are also under investigation for roles in neurodegenerative conditions via systemic metabolic and immunological pathways. However, “effects on gut microbiome” does not refer to a single protein/receptor/enzyme/transporter but rather describes an outcome or therapeutic strategy involving complex ecological shifts within host-associated microbes.

Other names
Gut microbiome modulationMicrobiome effectsMicrobiota alterationGut microbial composition changes
02

Mechanism of action

Not applicable to a specific molecular target; general mechanisms include: Restoration or modulation of microbial balance in the gut through introduction or support of beneficial bacteria/probiotics/prebiotics/FMT/phages; Alteration in metabolite production affecting host physiology and immune responses.

03

Biological functions

Modulation of immune responseMaintenance of gut barrier integrityRegulation of inflammationMetabolite production (e.g., short-chain fatty acids)Influence on host metabolism and neurological function
04

Disease associations

Gastrointestinal diseases (e.g., irritable bowel syndrome, inflammatory bowel disease)Infection (e.g., Clostridium difficile infection)Neurodegenerative disease (e.g., Alzheimer’s disease via the microbiota-gut-brain axis)
05

Safety considerations

Risk of infection transmission with FMTUnpredictable long-term effects due to complex ecosystem interactionsPotential for antibiotic resistance development with phage therapy or broad-spectrum antibiotics disrupting the microbiome balance
06

Interacting drugs

Probiotics (Lactobacillus rhamnosus, Saccharomyces boulardii, E. coli Nissle 1917)

3 more in the full profile.

07

Biomarkers

Specific bacterial taxa abundance profiles (“enterotypes”)Levels of short-chain fatty acids (SCFAs), bile acids, tryptophan metabolitesExpression levels of tight junction proteins in intestinal tissue

Beyond the preview

Go deeper on Effects on gut microbiome.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Effects on gut microbiome.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call